OR-RADISYS
8.3.2022 14:02:11 CET | Business Wire | Press release
Radisys® Corporation , a global leader of open telecom solutions, today announced that Celona , a leading innovator of private 5G solutions, has selected Radisys’ Connect RAN 5G Software to speed the deployment of its end-to-end 5G LAN solution.
News Highlights
- Private cellular networks continue to gain traction as more enterprises realize the distinct advantages of deploying their own 4G and 5G networks to support specific use cases that demand the highest levels of deterministic wireless connectivity. 5G private networks uniquely deliver to organizations a myriad of benefits over conventional wireless alternatives including greater control over user access, data confidentiality, network performance and quality of service levels. All traffic types generated within a private network are processed locally to ensure the highest security, data privacy, and lowest latency for enterprise applications vital to improving business productivity.
- Celona’s end-to-end 5G LAN delivers a fully-integrated private wireless solution purpose-built for enterprise use. With it, enterprises can better address the new connectivity needs of next-generation AI-based and edge-compute powered applications. Celona’s 5G LAN solution is offered as a subscription-based service with all hardware and software components optimized for seamless integration of cellular wireless with existing enterprise IT infrastructures.
- Radisys’ industry-leading 3GPP Release 16 compliant Connect RAN 5G CU/DU software, with the flexibility of Opt-2 and Opt-6 functional splits and single to multi-carrier support with bandwidths ranging from 10 MHz to 100 MHz for DL and UL-heavy TDD slot configurations, is most suitable for shared spectrum deployments. Radisys’ software is performance optimized for ARM based SoC, with an option for Cloud deployment and provides a rich feature set, enabling a faster time-to-market for Celona.
Puneet Shetty, VP of Product Management from Celona said: “To take full advantage of the benefits of 5G private networks, enterprises need access to cloud-native software that easily integrates with their current IT infrastructure. Radisys’ 5G RAN gNB CU/DU software has allowed us to quickly develop a unique turnkey LTE/5G LAN that gives enterprises the power to quickly deploy, own and operate their own private mobile network.”
Munish Chhabra, SVP and general manager of Mobility Software and Services Business, Radisys, said: “Radisys’ award-winning Connect RAN software helps Celona accelerate its 5G LAN time-to-market, and we are pleased to partner with Celona to deliver a complete solution for private network deployments. Radisys’ Connect RAN software is integral to enabling private networks that support ultra-low latency, high network availability, high device density capabilities for enterprise 5G services.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.Radisys.com .
About Celona
Celona, the enterprise 5G company, is focused on accelerating the adoption of business-critical apps on enterprise wireless and helping organizations implement a new generation of digital business initiatives. Taking advantage of dynamic spectrum sharing options such as CBRS in the United States, Celona’s Edgeless Enterprise architecture is designed to automate the adoption of 5G cellular wireless technology by enterprise organizations and their technology partners. For more information, please visit celona.io and follow Celona on Twitter @celonaio.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308005006/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom